AIM ImmunoTech (AIM) Provides Update on Jorgl Activist Group Litigation

Go back to AIM ImmunoTech (AIM) Provides Update on Jorgl Activist Group Litigation

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

August 15, 2022 4:05 PM UTC

OCALA, Fla.--(BUSINESS WIRE)-- AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order (TRO) sought by activist shareholder Jonathan Jorgl:

This morning we announced in a Form 10-Q filing that on August 12, 2022, a hearing was held in the Delaware Court of Chancery concerning a motion for a temporary restraining order sought by... More